CD44 as a potential diagnostic tumor marker

References

1. ↵
   1. Gee K,
   2. Kryworuchko M,
   3. Kumar A

   (2004) Recent advances in the regulation of CD44 expression and its role in inflammation and autoimmune diseases. Arch Immunol Ther Exp (Warsz) 52:13–26.

   OpenUrlPubMed
2. ↵
   1. Olsson E,
   2. Honeth G,
   3. Bendahl PO,
   4. Saal LH,
   5. Gruvberger-Saal S,
   6. Ringnér M,
   7. et al.

   (2011) CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11:418.

   OpenUrlCrossRefPubMed
3. ↵
   1. Akisik E,
   2. Bavbek S,
   3. Dalay N

   (2002) CD44 variant exons in leukemia and lymphoma. Pathol Oncol Res 8:36–40.

   OpenUrlCrossRefPubMed
4. ↵
   1. Hegde VL,
   2. Singh NP,
   3. Nagarkatti PS,
   4. Nagarkatti M

   (2008) CD44 mobilization in allogeneic dendritic cell-T cell immunological synapse plays a key role in T cell activation. J Leukoc Biol 84:134–142.

   OpenUrlCrossRefPubMed
5. ↵
   1. Termeer C,
   2. Averbeck M,
   3. Hara H,
   4. Eibel H,
   5. Herrlich P,
   6. Sleeman J,
   7. et al.

   (2003) Targeting dendritic cells with CD44 monoclonal antibodies selectively inhibits the proliferation of naive CD4+T-helper cells by induction of FAS-independent T-cell apoptosis. Immunology 109:32–40.

   OpenUrlCrossRefPubMed
6. ↵
   1. Guo W,
   2. Frenette PS

   (2014) Alternative CD44 splicing in intestinal stem cells and tumorigenesis. Oncogene 33:537–538.

   OpenUrlCrossRefPubMed
7. ↵
   1. Williams K,
   2. Motiani K,
   3. Giridhar PV,
   4. Kasper S

   (2013) CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) 238:324–338.

   OpenUrlCrossRefPubMed
8. ↵
   1. Bennett KL,
   2. Jackson DG,
   3. Simon JC,
   4. Tanczos E,
   5. Peach R,
   6. Modrell B,
   7. et al.

   (1995) CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 128:687–698.

   OpenUrlAbstract/FREE Full Text
9. ↵
   1. Delon I,
   2. Brown NH

   (2007) Integrins and the actin cytoskeleton. Curr Opin Cell Biol 19:43–50.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Okuda H,
    2. Kobayashi A,
    3. Xia B,
    4. Watabe M,
    5. Pai SK,
    6. Hirota S,
    7. et al.

    (2012) Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res 72:537–547.

    OpenUrlAbstract/FREE Full Text
11. ↵
    1. Afify A,
    2. Purnell P,
    3. Nguyen L

    (2009) Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol 86:95–100.

    OpenUrlCrossRefPubMed
12. ↵
    1. Fillmore C,
    2. Kuperwasser C

    (2007) Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res 9:303.

    OpenUrlCrossRefPubMed
13. ↵
    1. Li X,
    2. Lewis MT,
    3. Huang J,
    4. Gutierrez C,
    5. Osborne CK,
    6. Wu MF,
    7. et al.

    (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Zwick E,
    2. Bange J,
    3. Ullrich A

    (2001) Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8:161–173.

    OpenUrlAbstract
15. ↵
    1. Bourguignon LY,
    2. Zhu H,
    3. Chu A,
    4. Iida N,
    5. Zhang L,
    6. Hung MC

    (1997) Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem 272:27913–27918.

    OpenUrlAbstract/FREE Full Text
16. ↵
    1. Meran S,
    2. Luo DD,
    3. Simpson R,
    4. Martin J,
    5. Wells A,
    6. Steadman R,
    7. et al.

    (2011) Hyaluronan facilitates transforming growth factor-ß1-dependent proliferation via CD44 and epidermal growth factor receptor interaction. J Biol Chem 286:17618–17630.

    OpenUrlAbstract/FREE Full Text
17. ↵
    1. Chitnis MM,
    2. Yuen JS,
    3. Protheroe AS,
    4. Pollak M,
    5. Macaulay VM

    (2008) The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14:6364–6370.

    OpenUrlAbstract/FREE Full Text
18. ↵
    1. Bao W,
    2. Fu HJ,
    3. Xie QS,
    4. Wang L,
    5. Zhang R,
    6. Guo ZY,
    7. et al.

    (2011) HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology 141:2076–2087.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    1. Ishimoto T,
    2. Nagano O,
    3. Yae T,
    4. Tamada M,
    5. Motohara T,
    6. Oshima H,
    7. et al.

    (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19:387–400.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    1. Ghaffari S,
    2. Dougherty GJ,
    3. Lansdorp PM,
    4. Eaves AC,
    5. Eaves CJ

    (1995) Differentiation-associated changes in CD44 isoform expression during normal hematopoiesis and their alteration in chronic myeloid leukemia. Blood 86:2976–2985.

    OpenUrlAbstract/FREE Full Text
21. ↵
    1. Jin L,
    2. Hope KJ,
    3. Zhai Q,
    4. Smadja-Joffe F,
    5. Dick JE

    (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12:1167–1174.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    1. Sconocchia G,
    2. Campagnano L,
    3. Adorno D,
    4. Iacona A,
    5. Cococcetta NY,
    6. Boffo V,
    7. et al.

    (2001) CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production. Blood 97:3621–3627.

    OpenUrlAbstract/FREE Full Text
23. ↵
    1. Xie Z,
    2. Choong PF,
    3. Poon LF,
    4. Zhou J,
    5. Khng J,
    6. Jasinghe VJ,
    7. et al.

    (2008) Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol 62:949–957.

    OpenUrlCrossRefPubMed
24. ↵
    1. Zhang S,
    2. Wu CC,
    3. Fecteau JF,
    4. Cui B,
    5. Chen L,
    6. Zhang L,
    7. et al.

    (2013) Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A 110:6127–6132.

    OpenUrlAbstract/FREE Full Text
25. ↵
    1. Gadhoum Z,
    2. Leibovitch MP,
    3. Qi J,
    4. Dumenil D,
    5. Durand L,
    6. Leibovitch S,
    7. et al.

    (2004) CD44: a new means to inhibit acute myeloid leukemia cell proliferation via p27Kip1. Blood 103:1059–1068.

    OpenUrlAbstract/FREE Full Text
26. ↵
    1. Van Etten RA

    (2013) New insights into the normal and leukemic stem cell niche: a timely review. Cytometry B Clin Cytom 84:5–6.

    OpenUrl
27. ↵
    1. Alam TN,
    2. O’Hare MJ,
    3. Laczkó I,
    4. Freeman A,
    5. Al-Beidh F,
    6. Masters JR,
    7. et al.

    (2004) Differential expression of CD44 during human prostate epithelial cell differentiation. J Histochem Cytochem 52:1083–1090.

    OpenUrlCrossRefPubMed
28. ↵
    1. Zöller M

    (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11:254–267.

    OpenUrlCrossRefPubMedWeb of Science